The Food and Drug Administration has given emergency approval to a plan to distribute millions of doses of anti-malarial drugs to hospitals across the country, saying it is worth the risk of trying unproven treatments to slow the progression of the disease in seriously ill coronavirus patients.
Lilly teams with British startup to develop autoimmune medicines
In a deal that could eventually be worth close to a billion dollars, Eli Lilly and Co. is teaming with a British biopharmaceutical company in one of the hottest areas in medical research.Read More
Lilly teams with Canadian biotech in race to find treatment for COVID-19
The Indianapolis-based drugmaker said it will combine its capability for quickly developing antibodies with AbCellera’s “rapid pandemic response platform,” with the goal of getting a treatment into clinics for human testing within four months.Read More
Frustrated health consumers turn to apps, websites to find lowest drug prices
In recent years, a host of online websites and smartphone apps—such as GoodRx, Blink Health and Script Saver—have popped up to help people find the lowest price for prescription medicines. By using them, consumers can save thousands of dollars a year on their prescriptions if they don’t mind shopping around and buying some of their drugs outside their insurance plans.Read More
Lilly reports strong fourth quarter on rising sales of Trulicity, Taltz
The Indianapolis-based drugmaker exceeded analyst expectations for both profit and revenue during the most recent quarter.Read More
Karuna Therapeutics Inc., a publicly traded biopharmaceutical company, is developing a potential blockbuster treatment for schizophrenia that got its start at Eli Lilly and Co. decades ago.
Experts who have studied the so-called “orphan drug” program say the company’s request—and the FDA’s decision to grant it—seem inappropriate given the rapidly expanding threat of the viral outbreak. A financial analyst, though, called Gilead’s request “pretty standard.”
Eli Lilly and Co. said it considered sites in Indianapolis and Pennsylvania but chose North Carolina for quality of life, cost of operations and geographical diversity.
Under fire over insulin prices, the Indianapolis-based drugmaker said Tuesday morning it is introducing lower-priced versions of its Humalog KwikPen and Humalog Junior KwikPen.
Analysts have said that Dermira’s lead pipeline product, lebrikizumab, has the potential to be the best in class among a wave of similar antibodies to treat eczema.
To satisfy House Democrats, the Trump administration removed a provision that would have given the makers of ultra-expensive biologic drugs 10 years of protection from less expensive knockoffs.
The legislation has no chance of passing the Republican-controlled Senate, and the White House has issued a veto threat. Still, Democrats saw a victory in the message their bill sends to voters.
Though modest, it was the first such price drop in 45 years, according to nonpartisan economic experts at the federal Department of Health and Human Services, who deliver an annual report on the nation’s health care spending.
As a hammer to force companies to negotiate, House Speaker Nancy Pelosi would impose steep sales taxes on the medications at issue. Overall, budget analysts estimated the legislation would cut industry revenues by $500 billion to $1 trillion over 10 years.
As open enrollment goes into the home stretch Thanksgiving week, critics say the new tool can create confusion by obscuring out-of-pocket costs that seniors should factor into their decisions.
The pharmaceutical giant says it needs additional manufacturing capacity to keep up with demand for current medicines and new drugs expected to emerge from its pipeline.
A Gallup-West Health poll finds that 66 percent of adults don’t believe the Trump administration has made any progress, or very much progress, in limiting the rising cost of prescription drugs.
President Trump is instead backing a bipartisan bill that would for the first time limit what seniors have to pay out of their own pockets for medications.
The company said Monday that it will close 150 Walgreens-run clinics by the end of the year, but it will keep open more than 200 that are run in partnership with health care providers.
Digging through old data to salvage a seemingly failed Alzheimer’s drug paid off big time for Biogen Inc., but at least one of its rivals has no plans to follow suit.
President Donald Trump and House Speaker Nancy Pelosi could hardly be more at odds—but behind the scenes, they’re still grasping at a bipartisan deal to lower the cost of prescription drugs.
Eli Lilly and Co. easily topped earnings expectations in the third quarter, but shares in the Indianapolis-based drug company tumbled nearly 5 percent Wednesday morning.
Seven months after clinical trials for a promising Alzheimer’s drug were halted and the treatment was declared a failure, a new analysis suggests it was actually effective, and the company that makes it plans to move forward in securing federal approval.